Dr Gary Nabel has been appointed as Sanofi’s new senior VP and chief scientific officer and deputy to the president for global R&D, effective from 3 December.
Dr Nabel joins Sanofi from the National Institutes of Health, where he served as director of the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases since 1999.
During his tenure at the NIH, Dr Nabel provided overall direction and scientific leadership of the basic, clinical, and translational research activities of the VRC and guides development of novel vaccine strategies against HIV and other emerging and re-emerging infectious diseases, including Ebola/Marburg haemorrhagic fevers, influenza, chikungunya and other viruses.
In his new position, Dr Nabel will be responsible for assessing and coordinating Sanofi’s scientific direction for biopharmaceuticals, vaccines and animal health with a focus on improving translational approaches across Sanofi.
In his role, he will lead the evaluation of scientific quality of projects and programmes across all of R&D, and participate in setting Sanofi’s overall strategy.
